Fat: quality or quantity? What matters most for the progression of Metabolic Associated Fatty Liver Disease (MAFLD).

Objectives: Lately, many countries have restricted or even banned transfat, and palm oil has become a preferred replacement for food manufacturers. Whether palm oil is potentially an unhealthy food mainly due to its high content of saturated Palmitic Acid (PA) is a matter of debate. The aim of this...

ver descrição completa

Detalhes bibliográficos
Autores: Estévez Vázquez, Olga, Benede Ubieto, Raquel, Sanz García, Carlos, Maranillo Alcaide, Eva, Sañudo Tejero, José Ramón, Vázquez Osorio, María Teresa, Lamas Paz, Arantza, Peligros Gómez, María Isabel, Vaquero, Javier, Martínez Naves, Eduardo, Regueiro González-Barros, José Ramón
Formato: artículo
Fecha de publicación:2021
País:España
Recursos:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/107383
Acesso em linha:https://hdl.handle.net/20.500.14352/107383
Access Level:acceso abierto
Palavra-chave:612.017
obesity
metabolic associated fatty liver disease (MAFLD)
steatohepatitis
fibrosis
palmitic acid (PA)
Inmunología
2412 Inmunología
id ES_ea3e41fcbe5991462b5696e48bf01f14
oai_identifier_str oai:docta.ucm.es:20.500.14352/107383
network_acronym_str ES
network_name_str España
repository_id_str
spelling Fat: quality or quantity? What matters most for the progression of Metabolic Associated Fatty Liver Disease (MAFLD).Estévez Vázquez, OlgaBenede Ubieto, RaquelSanz García, CarlosMaranillo Alcaide, EvaSañudo Tejero, José RamónVázquez Osorio, María TeresaLamas Paz, ArantzaPeligros Gómez, María IsabelVaquero, JavierMartínez Naves, EduardoRegueiro González-Barros, José Ramón612.017obesitymetabolic associated fatty liver disease (MAFLD)steatohepatitisfibrosispalmitic acid (PA)Inmunología2412 InmunologíaObjectives: Lately, many countries have restricted or even banned transfat, and palm oil has become a preferred replacement for food manufacturers. Whether palm oil is potentially an unhealthy food mainly due to its high content of saturated Palmitic Acid (PA) is a matter of debate. The aim of this study was to test whether qualitative aspects of diet such as levels of PA and the fat source are risk factors for Metabolic Syndrome (MS) and Metabolic Associated Fatty Liver Disease (MAFLD). Methods: C57BL/6 male mice were fed for 14 weeks with three types of Western diet (WD): 1. LP-WD—low concentration of PA (main fat source—corn and soybean oils); 2. HP-WD—high concentration of PA (main fat source—palm oil); 3. HP-Trans-WD—high concentration of PA (mainly transfat). Results: All types of WD caused weight gain, adipocyte enlargement, hepatomegaly, lipid metabolism alterations, and steatohepatitis. Feeding with HP diets led to more prominent obesity, hypercholesterolemia, stronger hepatic injury, and fibrosis. Only the feeding with HP-Trans-WD resulted in glucose intolerance and elevation of serum transaminases. Brief withdrawal of WDs reversed MS and signs of MAFLD. However, mild hepatic inflammation was still detectable in HP groups. Conclusions: HP and HP-Trans-WD play a crucial role in the genesis of MS and MAFLD.MDPIUniversidad Complutense de Madrid20212021-01-0120212021-01-01journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/107383reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1073832026-06-02T12:44:21Z
dc.title.none.fl_str_mv Fat: quality or quantity? What matters most for the progression of Metabolic Associated Fatty Liver Disease (MAFLD).
title Fat: quality or quantity? What matters most for the progression of Metabolic Associated Fatty Liver Disease (MAFLD).
spellingShingle Fat: quality or quantity? What matters most for the progression of Metabolic Associated Fatty Liver Disease (MAFLD).
Estévez Vázquez, Olga
612.017
obesity
metabolic associated fatty liver disease (MAFLD)
steatohepatitis
fibrosis
palmitic acid (PA)
Inmunología
2412 Inmunología
title_short Fat: quality or quantity? What matters most for the progression of Metabolic Associated Fatty Liver Disease (MAFLD).
title_full Fat: quality or quantity? What matters most for the progression of Metabolic Associated Fatty Liver Disease (MAFLD).
title_fullStr Fat: quality or quantity? What matters most for the progression of Metabolic Associated Fatty Liver Disease (MAFLD).
title_full_unstemmed Fat: quality or quantity? What matters most for the progression of Metabolic Associated Fatty Liver Disease (MAFLD).
title_sort Fat: quality or quantity? What matters most for the progression of Metabolic Associated Fatty Liver Disease (MAFLD).
dc.creator.none.fl_str_mv Estévez Vázquez, Olga
Benede Ubieto, Raquel
Sanz García, Carlos
Maranillo Alcaide, Eva
Sañudo Tejero, José Ramón
Vázquez Osorio, María Teresa
Lamas Paz, Arantza
Peligros Gómez, María Isabel
Vaquero, Javier
Martínez Naves, Eduardo
Regueiro González-Barros, José Ramón
author Estévez Vázquez, Olga
author_facet Estévez Vázquez, Olga
Benede Ubieto, Raquel
Sanz García, Carlos
Maranillo Alcaide, Eva
Sañudo Tejero, José Ramón
Vázquez Osorio, María Teresa
Lamas Paz, Arantza
Peligros Gómez, María Isabel
Vaquero, Javier
Martínez Naves, Eduardo
Regueiro González-Barros, José Ramón
author_role author
author2 Benede Ubieto, Raquel
Sanz García, Carlos
Maranillo Alcaide, Eva
Sañudo Tejero, José Ramón
Vázquez Osorio, María Teresa
Lamas Paz, Arantza
Peligros Gómez, María Isabel
Vaquero, Javier
Martínez Naves, Eduardo
Regueiro González-Barros, José Ramón
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv 612.017
obesity
metabolic associated fatty liver disease (MAFLD)
steatohepatitis
fibrosis
palmitic acid (PA)
Inmunología
2412 Inmunología
topic 612.017
obesity
metabolic associated fatty liver disease (MAFLD)
steatohepatitis
fibrosis
palmitic acid (PA)
Inmunología
2412 Inmunología
description Objectives: Lately, many countries have restricted or even banned transfat, and palm oil has become a preferred replacement for food manufacturers. Whether palm oil is potentially an unhealthy food mainly due to its high content of saturated Palmitic Acid (PA) is a matter of debate. The aim of this study was to test whether qualitative aspects of diet such as levels of PA and the fat source are risk factors for Metabolic Syndrome (MS) and Metabolic Associated Fatty Liver Disease (MAFLD). Methods: C57BL/6 male mice were fed for 14 weeks with three types of Western diet (WD): 1. LP-WD—low concentration of PA (main fat source—corn and soybean oils); 2. HP-WD—high concentration of PA (main fat source—palm oil); 3. HP-Trans-WD—high concentration of PA (mainly transfat). Results: All types of WD caused weight gain, adipocyte enlargement, hepatomegaly, lipid metabolism alterations, and steatohepatitis. Feeding with HP diets led to more prominent obesity, hypercholesterolemia, stronger hepatic injury, and fibrosis. Only the feeding with HP-Trans-WD resulted in glucose intolerance and elevation of serum transaminases. Brief withdrawal of WDs reversed MS and signs of MAFLD. However, mild hepatic inflammation was still detectable in HP groups. Conclusions: HP and HP-Trans-WD play a crucial role in the genesis of MS and MAFLD.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/107383
url https://hdl.handle.net/20.500.14352/107383
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423122998886400
score 15,198674

Registos relacionados